75A50120C00177↗
Vedanta Biosciences, Inc. received this contract from Barda - Aspr / Daappo / Barda Dcma, Office of Assistant Secretary for Preparedness and Response: $63.00M obligated so far for r&d- other research and development (advanced development). It runs to 2027-08-31, or to 2031-12-31 if every option is exercised.
Key facts · data as of Oct 23, 2026
- Recipient
- Vedanta Biosciences, Inc.
- Awarding agency
- Office of Assistant Secretary for Preparedness and Response (Department of Health and Human Services)
- Contracting office
- Barda - Aspr / Daappo / Barda Dcma (75A501)
- Obligated to date
- $63.00M
- Potential value
- $134.15M
- Ends
- 2027-08-31
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 23, 2026.
Cite this page: SpendQuery, Award 75A50120C00177, data as of Oct 23, 2026, https://spendquery.com/award?id=CONT_AWD_75A50120C00177_7505_-NONE-_-NONE-
Vedanta Biosciences, Inc.: all federal awards · Department of Health and Human Services: spending · Barda - Aspr / Daappo / Barda Dcma: what it buys · The follow-on: recompete brief
TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS.
Up for re-bid: ends 2027-08-31. Recompete brief → · J&A to extend Period or Performance for procurement of Inmazeb ↗
What it is
- Product or service
- R&D- Other Research and Development (Advanced Development) (PSC AZ13)
- Industry
- Research and Development in Biotechnology (Except Nanobiotechnology) (NAICS 541714)
- Contracting office
- Barda - Aspr / Daappo / Barda Dcma (75A501)
- Competition
- Full and open competition · 1 offer received
- Pricing
- Cost sharing
- How it was bought
- Standalone contract
- Solicitation
- BAA-18-100-SOL-00003
- Where the work is
- Suffolk, MA · district MA-08
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
12 actions since 2023-02-27. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-07-21 | P00018 | Supplemental agreement (work within scope) | $0 | TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS- UPDATE KEY PERSONNEL |
| 2026-06-30 | P00017 | Supplemental agreement (work within scope) | $20.00M | EO14042 TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS. |
| 2026-04-02 | P00016 | Supplemental agreement (work within scope) | $0 | EO14042 TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS. |
| 2025-12-03 | P00015 | Supplemental agreement (work within scope) | $0 | EO14042 TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS. |
| 2025-09-23 | P00014 | Administrative change | $0 | EO14042 TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS. |
| 2025-05-16 | P00013 | Supplemental agreement (work within scope) | $12.50M | EO14042 TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS. |
| 2025-02-18 | P00012 | Supplemental agreement (work within scope) | $5.50M | EO14042 TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS. |
| 2024-07-17 | P00011 | Supplemental agreement (work within scope) | $10.00M | EO14042 TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS. |
| 2024-04-26 | P00010 | Supplemental agreement (work within scope) | $0 | EO14042 TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS. |
| 2024-02-14 | P00009 | Supplemental agreement (work within scope) | $15.00M | EO14042 TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS. |
| 2023-04-07 | P00008 | Administrative change | $0 | EO14042 TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS. |
| 2023-02-27 | P00007 | Administrative change | $0 | EO14042 TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS. |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-23). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗